Removing hepatitis C antibody testing for Australian blood donations: A cost-effectiveness analysis
- PMID: 37183482
- PMCID: PMC10952740
- DOI: 10.1111/vox.13429
Removing hepatitis C antibody testing for Australian blood donations: A cost-effectiveness analysis
Abstract
Background and objectives: The risk of transfusion-transmitted hepatitis C virus (HCV) infections is extremely low in Australia. This study aims to conduct a cost-effectiveness analysis of different testing strategies for HCV infection in blood donations.
Materials and methods: The four testing strategies evaluated in this study were universal testing with both HCV antibody (anti-HCV) and nucleic acid testing (NAT); anti-HCV and NAT for first-time donations and NAT only for repeat donations; anti-HCV and NAT for transfusible component donations and NAT only for plasma for further manufacture; and universal testing with NAT only. A decision-analytical model was developed to assess the cost-effectiveness of alternative HCV testing strategies. Sensitivity analysis and threshold analysis were conducted to account for data uncertainty.
Results: The number of potential transfusion-transmitted cases of acute hepatitis C and chronic hepatitis C was approximately zero in all four strategies. Universal testing with NAT only was the most cost-effective strategy due to the lowest testing cost. The threshold analysis showed that for the current practice to be cost-effective, the residual risks of other testing strategies would have to be at least 1 HCV infection in 2424 donations, which is over 60,000 times the baseline residual risk (1 in 151 million donations).
Conclusion: The screening strategy for HCV in blood donations currently implemented in Australia is not cost-effective compared with targeted testing or universal testing with NAT only. Partial or total removal of anti-HCV testing would bring significant cost savings without compromising blood recipient safety.
Keywords: blood donation testing; blood safety; cost effectiveness; hepatitis C.
© 2023 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.
Conflict of interest statement
All authors declare no conflicts of interest.
Figures
References
-
- Kirby Institute UNSW Sydney and Australian Red Cross Lifeblood . Transfusion‐transmissible infections in Australia: 2022 surveillance report. Available from: https://kirby.unsw.edu.au/report/transfusion-transmissible-infections-au...
-
- Kirby Institute UNSW Sydney, the Australian Red Cross Blood Service . Transfusion‐transmissible infections in Australia: 2020 surveillance report. Available from: https://kirby.unsw.edu.au/report/transfusion-transmissible-infections-au...
-
- Bruhn R, Lelie N, Busch M, Kleinman S. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion. 2015;55:1195–205. - PubMed
-
- Centers for Disease Control and Prevention . Blood safety basics. Available from: https://www.cdc.gov/bloodsafety/basics.html
-
- Joint United Kingdome Blood Transfusion and Tissue Transplantation Services. Guidelines for the blood transfusion services in the United Kingdom. 8th ed. London: Stationery Office; 2013.
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical